<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5642">
  <stage>Registered</stage>
  <submitdate>14/12/2012</submitdate>
  <approvaldate>14/12/2012</approvaldate>
  <nctid>NCT01751776</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-004090-16</secondaryid>
    <secondaryid>1293.2</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthritis, Rheumatoid</healthcondition>
    <healthcondition>Healthy</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BI 655064 medium dose
Treatment: drugs - BI 655064 high dose
Treatment: drugs - BI 655064 high dose
Treatment: drugs - Placebo
Treatment: drugs - BI 655064 low dose
Treatment: drugs - Placebo
Treatment: drugs - BI 655064 medium dose

Experimental: BI 655064 Part 1 - 3 different doses plus placebo in healthy volunteers

Experimental: BI 655064 Part 2 - 2 different doses plus placebo in rheumatoid arthritis patients


Treatment: drugs: BI 655064 medium dose
Medium dose

Treatment: drugs: BI 655064 high dose
High dose

Treatment: drugs: BI 655064 high dose
High dose

Treatment: drugs: Placebo
Placebo

Treatment: drugs: BI 655064 low dose
Low dose

Treatment: drugs: Placebo
Placebo

Treatment: drugs: BI 655064 medium dose
Medium dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary PK endpoint (Part 1): Cmax (after first and 4th dose)</outcome>
      <timepoint>up to Day 64 post-treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary PK endpoint (Part 1): AUC 0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinite)</outcome>
      <timepoint>Up to Day 64 post-treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary PK endpoint (Part 1): AUC t,4 (Area under the concentration-time curve of the analyte in plasma after the 4th dose over a uniform dosing interval t) after the first and 4th dose)</outcome>
      <timepoint>Up to Day 64 post-treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with drug related Adverse Events (Part 1).</outcome>
      <timepoint>Up to Day 64 post-treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ACR20 (American College of Rheumatology) response rate at week 12 (day 85) from the initiation of study treatment (Part 2)</outcome>
      <timepoint>week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>ACR50 and 70 response rates at week 12 (day 85) (Part 2)</outcome>
      <timepoint>week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>EULAR (European League Against Rheumatism) response criteria (DAS28 4v-CRP and DAS 28 4v-ESR) at week 12 (day 85) (Part 2)</outcome>
      <timepoint>week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with a decrease in DAS28 4v-CRP of &gt;1.2 at week 12 (day 85) compared to baseline (Part 2)</outcome>
      <timepoint>baseline and week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in DAS28-4v at week 12 (day 85) compared to baseline (Part 2)</outcome>
      <timepoint>baseline and week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

        Part 1 (phase Ib) (HVs):

          1. Healthy males and females according to the investigators assessment, as based on the
             following criteria: a complete medical history including a physical examination, vital
             signs (BP, PR), 12-lead ECG, and clinical laboratory tests

          2. Age &gt;= 18 and &lt;= 60 years

          3. Body Mass Index &gt;= 18.5 and &lt;= 29.9 kg/m2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

          5. Female subjects who meet any of the following criteria from at least 30 days before
             the first study drug administration and until 30 days after trial completion:

               -  using adequate contraception, e.g. any of the following methods plus condom:
                  implants, injectables, combined oral contraceptives, intrauterine device (IUD)

               -  sexually abstinent

               -  have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)

               -  surgically sterilised (including hysterectomy)

               -  postmenopausal defined as at least 1 year of spontaneous amenorrhea (in
                  questionable cases a blood sample with simultaneous levels of follicle
                  stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is
                  confirmatory)

        Part 2 (phase IIa) (RA Patients):

          1. Age &gt;= 18 and &lt;= 70 years

          2. Patients classified as having RA according to the 1987 ACR Classification Criteria

          3. Inadequate clinical response to methotrexate monotherapy defined as moderate/high
             active disease after oral or s.c. MTX treatment given continuously for at least 3
             months and for the last 6 weeks before screening at a stable weekly dose &gt;=15mg. For
             patients who do not tolerate the minimum weekly dose of at least 15 mg due to side
             effects, a stable weekly dose as low as 7.5 mg is also permitted.

          4. DAS28 4v-CRP &gt;= 3.5 with &gt;= 6 tender and &gt;= 6 swollen joints out of 68/66 joint count
             at screening and confirmed by &gt;= 6 tender and &gt;= 6 swollen joints out of 68/66 joint
             count only at randomisation visit (Visit 2)

          5. Serum CRP level &gt;= 0.8 mg/dL or ESR &gt;= 28 mm/1h at screening

          6. Anti-CCP2 or Rheumatoid Factor positivity as per the limits of used assay at screening

          7. Female patients who meet any of the following criteria from at least 30 days before
             the first study drug administration and until at least 6 months after last dose of MTX
             taken in the current trial:

             using adequate contraception, e.g. any of the following methods plus condom: implants,
             injectables, combined oral contraceptives, intrauterine device (IUD)

               -  sexually abstinent

               -  have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)

               -  surgically sterilised (including hysterectomy)

               -  postmenopausal defined as at least 1 year of spontaneous amenorrhea (in
                  questionable cases a blood sample with simultaneous levels of follicle
                  stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is
                  confirmatory)

             OR

             Male patients who:

               -  are documented to be sterile or consistently and correctly use a condom while
                  their female partners (if of childbearing potential) agree to use any of the
                  following adequate contraception methods: implants, injectables, combined oral
                  contraceptives, intrauterine device (IUD) from the date of screening until at
                  least 6 months after the last dose of MTX taken in the current trial

               -  donÂ¿t donate any sperm sample for procreation purposes, from the date of
                  screening until at least 6 months after last dose of MTX taken in the current
                  trial.

          8. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

        Part 1 (phase Ib in HVs):

          1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal
             and judged clinically relevant by the investigator

          2. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          3. Any evidence of a concomitant disease judged clinically relevant by the investigator

          4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          5. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders

          6. History of relevant orthostatic hypotension, fainting spells, or blackouts

          7. History of relevant allergy/hypersensitivity (including allergy to the trial
             medication or its excipients)

        9. Within 10 days prior to administration of trial medication, use of drugs that might
        reasonably influence the results of the trial 12. Alcohol abuse (consumption of more than
        140 g/week in females and 210 g/week in males) 13. Drug abuse or positive drug screen 17.
        Chronic or relevant acute infections, including but not limited to HIV, Hepatitis B and C
        and tuberculosis (including a history of clinical TB and/or a positive QuantiFERON TB-Gold
        test) 18. Subject is assessed by the investigator as unsuitable for inclusion e.g.
        considered not able to understand and comply with study requirements or has a condition
        that would not allow safe participation in the study 19. Positive pregnancy test, pregnancy
        or plans to become pregnant within 30 days after study completion 20. Lactation

        Further exclusion criteria applicable for part 1 only are given in the CTP.

        Part 2 (phase IIa in RA patients):

        Part 1 (phase Ib) exclusion criteria 7, 9, 12, 13 and 17-20 plus:

          1. Current or previous use of more than two anti-TNF biologic drugs or use of other
             biologic agent targeting any other approved mechanism (any biologic drug with
             mechanism of action other than direct anti-TNF blockade, (e.g. CTLA4, anti-IL6, or
             anti CD-20) or new oral compounds targeting any other approved mechanism (e.g. JAK
             inhibitors) for treating RA.

          2. Current or previous participation in a clinical trial testing an investigational drug
             for RA within 3 months prior to screening or within 5 half-lives of the
             investigational drug, whichever is longer , except of previous participation in trials
             testing NSAIDs, corticosteroids, analgesics or patients documented as receiving
             placebo in previous RA trials.

          3. DAS28 &lt; 3.2 in at least 2 occasions during the last 6 months before screening

          4. RA patients with severe disability (functional class IV) or with confirmed severe
             systemic manifestations e.g. known amyloidosis, FeltyÂ´s syndrome, lymphoproliferative
             disorders, rheumatoid vasculitis

          5. Treatment with any standard DMARD except MTX (including but not limited to
             sulfasalazine, leflunomide, hydroxychloroquine, D-penicillamine

          6. Impaired hepatic function, defined as serum AST/ALT, bilirubin or alkaline phosphatase
             levels &gt; 2 x ULN

          7. Impaired renal function defined as calculated creatinine clearance &lt; 50ml/min

          8. Pre-existing blood dyscrasias e.g. bone marrow hypoplasia, significant anaemia,
             leucopenia or thrombocytopenia

          9. Hypersensitivity to MTX or any of its excipients

         10. Previous intolerance to MTX as the main cause for stopping treatment (instead of lack
             of efficacy)

         11. Any active or suspected malignancy or history of documented malignancy within the last
             5 years before screening, except appropriately treated basal cell carcinoma of the
             skin or in situ carcinoma of uterine cervix.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>107</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Kreuznach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>MÃ¼nchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Zerbst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leeuwarden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sneek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton Auckland NZ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A CoruÃ±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Laguna (Sta Cruz Tenerife)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and tolerability of multiple doses of BI 655064 administered
      subcutaneously in healthy volunteers (HVs) and in rheumatoid arthritis (RA) patients. To
      explore the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of multiple doses of BI
      655064 in healthy volunteers (HVs) and rheumatoid arthritis (RA) patients. To assess clinical
      effect of BI 655064 in RA patients with prior inadequate response to methotrexate (MTX) after
      12 weeks of treatment</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01751776</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>